Analgesic medications compounded for topical use are gaining popularity for the management of chronic pain. The advantages of topical pain medications include reduction of systemic adverse effects, improved patient acceptance, few drug interactions, ease of dose determination, avoidance of first-pass metabolism, and direct access to the target site. Compounded topical medications typically use a mixture of 3 or more single medications to achieve multiple complementary effects at lower doses of each individual medication. Herein, we review the mechanisms, adverse effects, and evidence for some of the most commonly used medications in topical compounds for pain management. Because more topical medications are used for chronic pain, dermatologists can expect an increase in irritant and allergic contact dermatitis related to these medications.
Get full access to this article
View all access options for this article.
References
1.
ComptonWM, VolkowND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend, 2006; 81(2):103–107.
2.
CairnsBE. Peripheral Receptor Targets for Analgesia: Novel Approaches to Pain Management. New Jersey, NJ: Wiley; 2009.
3.
ArgoffCE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc, 2013; 88(2):195–205.
4.
ZurE. Topical treatment of neuropathic pain using compounded medications. Clin J Pain, 2014; 30(1):73–91.
5.
ZempskyW. Topical analgesics in treating neuropathic and musculoskeletal pain. Pain Medicine News, 2013; 11(10):7–10.
6.
JonesM. Chronic neuropathic pain: pharmacological interventions in the new millennium. Int J Pharm Compd, 2000; 4(1):6–15.
7.
WarnerM, TuderD. A brief survey on prescriber beliefs regarding compounded topical pain medications. Int J Pharm Compd, 2014; 18(3):182–188.
8.
BennettA.Topical prescription creams reduce pain in five of every six chronic pain patients, without need for opioids or other narcotics. Patient Outcomes Analytics; 2013. Available at: http://globenewswire.com/. Accessed January19, 2016.
9.
LynchME, ClarkAJ, SawynokJ, et al.Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology, 2005; 103(1):140–146.
10.
MahoneyJM, VardaxisV, MooreJL, et al.Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc, 2012; 102(3):178–183.
11.
BarrosGA, MiotHA, BrazAM, et al.Topical (S)-ketamine for pain management of postherpetic neuralgia. An Bras Dermatol, 2012; 87(3):504–505.
12.
BoardmanLA, CooperAS, BlaisLR, et al.Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol, 2008; 112(3):579–585.
13.
CampbellCM, KipnesMS, StouchBC, et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain, 2012; 153(9):1815–1823.
14.
EpsteinJB, GrushkaM, LeN. Topical clonidine for orofacial pain: a pilot study. J Orofac Pain, 1997; 11(4):346–352.
15.
WrzosekA, WoronJ, DobrogowskiJ, et al.Topical clonidine for neuropathic pain. Cochrane Database Syst Rev, 2015; 8:Cd010967.
16.
HoKY, HuhBK, WhiteWD, et al.Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain, 2008; 24:(1)51–55.
17.
BinderA, BruxelleJ, RogersP, et al.Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig, 2009; 29:(6)393–408.
18.
DeversA, GalerBS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain, 2000; 16:(3)205–208.
19.
MeierT, WasnerG, FaustM, et al.Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain, 2003; 106:(1-2)151–158.
20.
MasonL, MooreRA, DerryS, et al.Systematic review of topical capsaicin for the treatment of chronic pain. BMJ, 2004; 328(7446):991.
21.
MaihofnerCG, HeskampML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain, 2014; 18(5):671–679.
22.
CasanuevaB, RoderoB, QuintialC, et al.Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatol Int, 2013; 33(10):2665–70. doi: 10.1007/s00296-012-2490-5.
23.
KulkantrakornK, LorsuwansiriC. Sensory profile and its impact on quality of life in patients with painful diabetic polyneuropathy. J Neurosci Rural Pract, 2013; 4(3):267–270.
24.
DerryS, MooreRA, GaskellH, et al.Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev, 2015; 6:CD007402.
25.
KimDH, YoonKB, ParkS, et al.Comparison of NSAID patch given as monotherapy and NSAID patch in combination with transcutaneous electric nerve stimulation, a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome of the upper trapezius: a pilot study. Pain Med, 2014; 15(12):2128–2138.
26.
AhmedSU, ZhangY, ChenL, et al.Effect of 1.5% topical diclofenac on clinical neuropathic pain. Anesthesiology, 2015; 123(1):191–198.
27.
GewandterJS, MohileSG, HecklerCE, et al.A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer, 2014; 22(7):1807–1814.
28.
BartonDL, WosEJ, QinR, et al.A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer, 2011; 19(6):833–841.
NyirjesyP, Lev-SagieA, MathewL, et al.Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Low Genit Tract Dis, 2009; 13(4).
31.
CoggeshallRE, CarltonSM. Receptor localization in the mammalian dorsal horn and primary afferent neurons. Brain Res Brain Res Rev, 1997; 24(1):28–66.
32.
KinkelinI, BrockerEB, KoltzenburgM, et al.Localization of ionotropic glutamate receptors in peripheral axons of human skin. Neurosci Lett, 2000; 283(2):149–152.
AnisNA, BerrySC, BurtonNR, et al.The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol, 1983; 79(2):565–575.
35.
EbertB, MikkelsenS, ThorkildsenC, et al.Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol, 1997; 333(1):99–104.
36.
BackonjaM, ArndtG, GombarKA, et al.Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain, 1994; 56(1):51–57.
37.
Arendt-NielsenL, Petersen-FelixS, FischerM, et al.The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg, 1995; 81(1):63–68.
38.
GrantIS, NimmoWS, ClementsJA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth, 1981; 53(8):805–810.
39.
EidePK, JørumE, StubhaugA, et al.Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain, 1994; 58(3):347–354.
40.
MercadanteS, LodiF, SapioM, et al.Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage, 1995; 10(7):564–568.
41.
CurranHV, MonaghanL. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 2001; 96(5):749–760.
42.
KronenbergRH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother, 2002; 16(3):27–35.
43.
GammaitoniA, GallagherRM, Welz-BosnaM. Topical ketamine gel: possible role in treating neuropathic pain. Pain Med, 2000; 1(1):97–100.
44.
CrowleyKL, FloresJA, HughesCN, et al.Clinical application of ketamine ointment in the treatment of sympathetically maintained pain. Int J Pharm Compd, 1998; 2(2):122–127.
45.
FinchPM, KnudsenL, DrummondPD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain, 2009; 146(1–2):18–25.
GidalBE. New and emerging treatment options for neuropathic pain. Am J Manag Care, 2006; 12(9suppl):S269–S278.
50.
GeeNS, BrownJP, DissanayakeVU, et al.The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem, 1996; 271(10):5768–5776.
51.
ShimoyamaM, ShimoyamaN, HoriY. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain, 2000; 85(3):405–414.
52.
SindrupSH, JensenTS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 1999; 83(3):389–400.
53.
PanHL, EisenachJC, ChenSR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther, 1999; 288(3):1026–1030.
54.
ManeufYP, GonzalezMI, SuttonKS, et al.Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci, 2003; 60(4):742–750.
55.
HonarmandA, SafaviM, ZareM. Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy. J Res Med Sci, 2011; 16(8):1062–1069.
56.
EdelsbergJS, LordC, OsterG. Systematic review and meta-analysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia. Ann Pharmacother, 2011; 45(12):1483–1490.
57.
MathewNT, RapoportA, SaperJ, et al.Efficacy of gabapentin in migraine prophylaxis. Headache, 2001; 41(2):119–128.
58.
RapchukIL, O’ConnellL, LiessmannCD, et al.Effect of gabapentin on pain after cardiac surgery: a randomised, double-blind, placebo-controlled trial. Anaesth Intensive Care, 2010; 38(3):445–451.
59.
DallocchioC, BuffaC, MazzarelloP, et al.Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage, 2000; 20(4):280–285.
60.
DahlJB, MathiesenO, MoinicheS. ‘Protective premedication’: an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol Scand, 2004; 48(9):1130–1136.
61.
MagalhaesE, MascarenhasAM, KraycheteDC, et al.Gabapentin to treat sacral perineural cyst-induced pain. Case report. Rev Bras Anestesiol, 2004; 54(1):73–77.
62.
RiedlMS, SchnellSA, OverlandAC, et al.Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol, 2009; 513(4):385–398.
63.
Lavand’hommePM, MaW, De KockM, et al.Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology, 2002; 97(4):972–980.
64.
HassenbuschSJ, GunesS, WachsmanS, et al.Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Med, 2002; 3(2):85–91.
65.
SierraltaF, NaquiraD, PinardiG, et al.alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception. Br J Pharmacol, 1996; 119(3):551–554.
66.
EisenachJC, DuPenS, DuboisM, et al.Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain, 1995; 61(3):391–399.
67.
DiasVC, TendlerB, OparilS, et al.Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. Am J Ther, 1999; 6(1):19–24.
68.
PuskasF, CarnporesiEM, O’LearyCE, et al.Intrathecal clonidine and severe hypotension after cardiopulmonary bypass. Anesth Analg, 2003; 97(5):1251–1253.
69.
Romero-SandovalA, EisenachJC. Perineural clonidine reduces mechanical hypersensitivity and cytokine production in established nerve injury. Anesthesiology, 2006; 104(2):351–355.
70.
DavisKD, TreedeRD, RajaSN, et al.Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain, 1991; 47(3):309–317.
71.
Byas-SmithMG, MaxMB, MuirJ, et al.Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain, 1995; 60(3):267–274.
72.
MaibachHI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis, 1987; 16(1):1–8.
73.
PolsterAM, WarnerMR, CamisaC. Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis, 1999; 63(3):154–155.
SandroniP, DavisMD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option?. Arch Dermatol, 2006; 142(3):283–286.
76.
KopskyDJ, HesselinkJM. High doses of topical amitriptyline in neuropathic pain: 2 cases and literature review. Pain Pract, 2012; 12(2):148–153.
77.
LehmanJS, SciallisGF. Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. J Drugs Dermatol, 2008; 7(9):887–889.
GernerP, KaoG, SrinivasaV, et al.Topical amitriptyline in healthy volunteers. Reg Anesth Pain Med, 2003; 28(4):289–293.
80.
SmithGD, HarrisonSM, BirchPJ, et al.Increased sensitivity to the antinociceptive activity of (+/−)-baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia. Neuropharmacology, 1994; 33(9):1103–1108.
81.
ReisGM, DuarteID. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol, 2006; 149(6):733–739.
82.
ArnoldLM, KeckPEJr, WelgeJA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics, 2000; 41(2):104–113.
83.
BrysonE, HartmanR, ArnoldJ, et al.Skin permeation and antinociception of compounded topical cyclobenzaprine hydrochloride formulations. Int J Pharm Compd, 2015; 19(2):161–166.
84.
TurrentineJE, MarrazzoG, CruzPDJr. Novel use of patch testing in the first report of allergic contact dermatitis to cyclobenzaprine. Dermatitis, 2015; 26(1):60–61.
85.
GammaitoniAR, DavisMW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother, 2002; 36(2):236–240.
86.
DerryS, WiffenPJ, MooreRA, et al.Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev, 2014; 7:Cd010958.
87.
WolffRF, BalaMM, WestwoodM, et al.5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand, 2011; 123(5):295–309.
88.
ArgoffCE, GalerBS, JensenMP, et al.Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin, 2004; 20(suppl 2):S21–S28.
89.
GammaitoniAR, AlvarezNA. 24-Hour application of the lidocaine patch 5% for 3 consecutive days is safe and well tolerated in healthy adult men and women. Pain Med, 2002; 3(2):172.
90.
UkensC. Coed death tied to compounded drug. 2005: Drug Topics.
91.
ToD, KossintsevaI, de GannesG. Lidocaine contact allergy is becoming more prevalent. Dermatol Surg, 2014; 40(12):1367–1372.
92.
WarshawEM, BelsitoDV, TaylorJS, et al.North American Contact Dermatitis Group patch test results: 2009 to 2010. Dermatitis, 2013; 24(2):50–59.
93.
WarshawEM, SchramSE, BelsitoDV, et al.Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis, 2008; 19(2):81–85.
94.
CunninghamAL, DworkinRH. The management of post-herpetic neuralgia. BMJ, 2000; 321(7264):778–779.
95.
KnotkovaH, PappagalloM, SzallasiA. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?. Clin J Pain, 2008; 24(2):142–154.
PeikertA, HentrichM, OchsG. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol, 1991; 238(8):452–456.
98.
NolanoM, SimoneDA, Wendelschafer-CrabbG, et al.Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain, 1999; 81(1–2):135–145.
99.
DerryS, MooreRA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev, 2012; 9:Cd010111.
100.
HeynemanCA, Lawless-LidayC, WallGC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs, 2000; 60(3):555–574.
101.
LinJ, ZhangW, JonesA, et al.Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ, 2004; 329(7461):324.
102.
MasonL, MooreRA, EdwardsJE, et al.Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord, 2004; 5:28.
103.
MasseyT, DerryS, MooreRA, et al.Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev, 2010;(6):Cd007402.
104.
FranckumJ, RamsayD, DasNG, et al.Pluronic lecithin organogel for local delivery of anti-inflammatory drugs. Int J Pharm Compd, 2004; 8(2):101–105.
105.
de PaulaE, CeredaCM, TofoliGR, et al.Drug delivery systems for local anesthetics. Recent Pat Drug Deliv Formul, 2010; 4(1):23–34.
106.
Zell-KanterM, ToerneTS, SpiegelK, et al.Doxepin toxicity in a child following topical administration. Ann Pharmacother, 2000; 34(3):328–329.
107.
LutwakN, HowlandMA, GambettaR, et al.Even ‘safe’ medications need to be administered with care. BMJ Case Rep, 2013; 2013: bcr2012006204.
108.
JorgeLL, FeresCC, TelesVE. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res, 2010; 4:11–24.
109.
de Leon-CasasolaOA. Multimodal approaches to the management of neuropathic pain: the role of topical analgesia. J Pain Symptom Manage, 2007; 33(3):356–364.
110.
DworkinRH, O’ConnorAB, AudetteJ, et al.Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc, 2010; 85(suppl 3):S3–S14.
